Vascepa 1 gram

Drug Amarin Pharma Inc.
Total Payments
$2.6M
Transactions
23
Doctors
0
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2019 $2.6M 23 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $2.6M 23 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Comprehensive Biomarker and Causal Mediation Analyses in REDUCE-IT Amarin Pharma Inc. $1.6M 0
Cost Effectiveness Analyses of REDUCE-IT Amarin Pharma Inc. $443,148 0
A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the effect of AMR101 on Cardiovascular Heath and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardio Amarin Pharma Inc. $250,864 0
Triglyceride Lowering Treatment Amarin Pharma Inc. $175,481 0
KP REACH Amarin Pharma Inc. $67,739 0
Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy Amarin Pharma Inc. $57,524 0

Top Doctors Receiving Payments for Vascepa 1 gram

Doctor Specialty Location Total Records
Unknown — Boston, MA $2.6M 23

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $2.6M
  • Total Doctors 0
  • Transactions 23

About Vascepa 1 gram

Vascepa 1 gram is a drug associated with $2.6M in payments to 0 healthcare providers, recorded across 23 transactions in the CMS Open Payments database. The primary manufacturer is Amarin Pharma Inc..

Payment data is available from 2019 to 2019. In 2019, $2.6M was paid across 23 transactions to 0 doctors.

The most common payment nature for Vascepa 1 gram is "Unspecified" ($2.6M, 100.0% of total).

Vascepa 1 gram is associated with 6 research studies, including "Comprehensive Biomarker and Causal Mediation Analyses in REDUCE-IT" ($1.6M).